Johnson & Johnson
Johnson & Johnson Completes Separation from Kenvue via Debt-for-Equity Exchange
Summary
On May 17, 2024, Johnson & Johnson (J&J) finalized its separation from Kenvue by completing a debt-for-equity exchange. J&J issued $3.6 billion in commercial paper on May 15, 2024, which was exchanged for its remaining Kenvue shares on May 17, 2024, effectively discharging the commercial paper and resulting in J&J no longer owning any Kenvue shares. This follows Kenvue's IPO in May 2023 and a subsequent share exchange in August 2023.
Profitelligence Alerts
Get alerts for JNJ
Be first to know when Johnson & Johnson files with the SEC.
Filing Categories
Advertisement
About Johnson & Johnson
Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.
Official SEC Documents
Advertisement